TITLE

Is your patient still using rosiglitazone?

AUTHOR(S)
Gov-Ari, Hanna K.; Stevermer, James J.
PUB. DATE
August 2011
SOURCE
Clinician Reviews;Aug2011, Vol. 21 Issue 8, p30
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that doctors have stopped prescribing rosiglitazone when a study linked it to an elevated myocardial infarction (MI) risk. That it is not advised to switch to pioglitazone instead of initiating rosiglitazone therapy for patients with diabetes is pointed out. Although removing the drug from the market received a majority vote at a U.S. Food and Drug Administration meeting, the motion was not carried out. Both drugs bear a black box warning regarding congestive heart failure.
ACCESSION #
65148271

 

Related Articles

  • Diabetes Medication Associated with Increased Risk of Heart Problems.  // O&P Business News;4/1/2008, Vol. 17 Issue 7, p71 

    The article highlights the study in the Journal of the American Medical Association on the risks of diabetes medications in the U.S. According to the author, the study shows that there is a significant increased risk of heart attack, congestive heart failure (CHF) and death to older patients...

  • FDA Panel: Keep Avandia on Market With Restrictions.  // Bioworld Week;7/19/2010, Vol. 18 Issue 29, p1 

    The article reports on the restrictions made by the panel of the U.S. Food and Drug Administration regarding the type II diabetes drug Avandia (rosiglitazone) from GlaxoSmithKline. It mentions the availability of the drug in the U.S. market despite the warnings and limited use related to heart...

  • FDA eliminating REMS for rosiglitazone.  // Reactions Weekly;1/9/2016, Vol. 1583 Issue 1, p8 

    The article reports that the U.S. Food and Drug Administration (FDA) is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone products as the benefits of the drug outweigh the risks, and removal of rosiglitazone does not increase the risk of myocardial infarction.

  • Responding to an FDA Warning � Geographic Variation in the Use of Rosiglitazone. Shah, Nilay D.; Montori, Victor M.; Krumholz, Harlan M.; Tu, Karen; Alexander, G. Caleb; Jackevicius, Cynthia A. // New England Journal of Medicine;11/25/2010, Vol. 363 Issue 22, p2081 

    The article discusses the results of the retrospective analysis that was conducted using the National Prescription Audit and the Xponent database to determine the impact of the boxed warning issued by the U.S. Food and Drug Administration (FDA) on the risk of myocardial infarction on the use of...

  • Nephrogenic Fibrosing Dermopathy: A Case Study. Sego, Sherril // Nephrology Nursing Journal;Jan/Feb2008, Vol. 35 Issue 1, p67 

    The article describes the case of a woman on hemodialysis who was presented to her nephrologists with complaints of worsening pain and stiffness in her hand and arms. It says that the patient had a complex history of poorly controlled type 1 diabetes from the age of 10, 2 myocardial infarction,...

  • TZDs linked with increased risk for heart problems, death. Haigh, Christen // Endocrine Today;1/10/2008, Vol. 6 Issue 1, p8 

    This article discusses research being done on the side effects of rosiglitazone in patients with diabetes. It references a study by L. L. Lipscombe et al., published in a 2007 issue of the "Journal of the American Medical Association." The study found that rosiglitazone was linked to an...

  • Is There Clear and Convincing Evidence of Cardiovascular Risk with Rosiglitazone? Kaul, S.; Diamond, G. A. // Clinical Pharmacology & Therapeutics;Jun2011, Vol. 89 Issue 6, p773 

    In this article, the author focuses on the cardiovascular safety of rosiglitazone, a thiazolidinedione drug designed for glycemic control among type 2 diabetics. The author states that meta-analyses conducted by the U.S. Food and Drug Administration (FDA) shows the association of rosiglitazone...

  • Rosiglitazone, Medical Reversal, and Back to Basics for Diabetes. PRASAD, VINAY // American Family Physician;9/15/2014, Vol. 90 Issue 6, p369 

    The author reflects on the adverse impact of medical reversals performed on the drug rosiglitazone on patients having diabetes. Topics discussed include restriction imposed by the U.S. Food and Drug Administration (FDA) in 2013 on the use of the drug, increased risk of myocardial ischemia due to...

  • Avandia Gets Over One FDA Hurdle. Comarow, Avery // U.S. News & World Report;8/13/2007, Vol. 143 Issue 5, p47 

    The article discusses the diabetes drug Avandia. The "New England Journal of Medicine" has found that Avandia users have a higher risk of heart attack. The Food and Drug Administration has plans to meet to review Avandia and a similar drug, Actos. People prone to congestive heart failure are...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics